MainBoardListed
Concord Biotech Limited
Company websiteInvestor note: Concord Biotech Limited aims to raise ₹2,09,25,652 crore. The fresh issue of ₹0 crore goes to the company while the OFS of ₹2,09,25,652 crore is an existing-shareholder sale.
Subscription window: 04-08-2023 to 08-08-2023. Allotment and listing timelines: 14-08-2023 / 18-08-2023. Tip: check promoter holding and recent financials before applying.
Start Date04-08-2023
End Date08-08-2023
Listing Date18-08-2023
Allotment Date14-08-2023
Current Price₹900.05
GMP₹125 (16.87%)
Lot Size20 Shares
Subscription26.13 Times
Face Value₹1 Per Share
Listing atNSE, BSE
Issue Price₹705 - ₹741
Pre Issue₹0
Post Issue₹10,46,16,204
Issue Size₹2,09,25,652
(aggregating up to 1551.00 Cr)
(aggregating up to 1551.00 Cr)
Fresh Issue
(aggregating up to 0.00 Cr)
(aggregating up to 0.00 Cr)
Offer For Sale₹2,09,25,652
(aggregating up to 1551.00 Cr)
(aggregating up to 1551.00 Cr)
The Grey Market Premium (GMP) for Concord Biotech Limited is currently around ₹125 (16.87%). This indicates an estimated listing price of approximately ₹830 based on the latest market sentiment. Please note that GMP values are unofficial and can change frequently as they depend on demand, market conditions, and investor activity.
Gmp Details
| Last Updated | IPO Price | GMP | Estimated Listing Price |
|---|---|---|---|
07 Nov 2025, 12:03 | ₹741 | ₹125 | ₹866 (16.87%) |
19 Mar 2025, 10:47 | ₹741 | ₹125 | ₹866 (16.87%) |
Financials overview In Crores
Here is a quick look at the recent financial performance of Concord Biotech Limited . The numbers below ( In Crores ) show how the company’s revenue and profits have changed over the last few years. This helps investors understand how strongly the business is growing and how stable its financial health is before applying for the IPO.
Key Performance
| KPI | Values |
|---|---|
EPS | 20.79 |
ROE | 20.06 |
ROCE | 24.27 |
RONW | 20 |
PRE IPO(PE) | 32.29 |
POST IPO(PE) | 0 |
Subscription Demand (in ₹ Crore)
| Category | Offered | Demand | Times |
|---|---|---|---|
QIBs | ₹294.91 | 20975.08 | 71.12 |
RETAIL | ₹516.09 | 2050.34 | 3.97 |
HNIs 2+ | ₹73.73 | 958.56 | 13.00 |
HNIs 10+ | ₹147.46 | 2991.27 | 20.29 |
EMPLOYEES | ₹0.70 | 18.13 | 25.90 |
Total | ₹1,032.89 | 26993.38 | 26.13 |
The IPO reservation for Concord Biotech Limited shows how the total issue is divided among different investor categories. This includes allocations for Retail Investors, Qualified Institutional Buyers (QIBs), and Non-Institutional Investors (NIIs). Understanding the reservation structure helps investors know how much of the issue is set aside for their category before applying.
IPO Reservation
| Category | Shares Offers | No. of Shares |
|---|---|---|
QIB | 49.98% | 1,04,57,825 |
NII (HNI) | 14.99% | 31,37,348 |
RETAIL | 34.98% | 73,20,479 |
Employee | 0.05% | 10,000 |
TOTAL | 100.00% | 2,09,25,652 |
Lot(s) Distribution
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
Retail (Min) | 1 | 20 | ₹14,820 | |
sHNI | 14 | 280 | ₹2,07,480 | |
bHNI | 68 | 1,360 | ₹10,07,760 |
Below you can find the official contact details of Concord Biotech Limited along with the registrar handling the IPO process. This information helps investors reach out for queries related to the company or for checking the allotment status and application updates once the IPO process begins.
Company Details
Phone: 079-6813 8700
Website: http://www.concordbiotech.com/
Address: 1482-86, Trasad Road Dholka, Ahmedabad – 382225
IPO Registrar
Name: Link Intime India Private Limited
Phone: +91-22-4918 6270